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We would like to thank Drs. Grosser, Naji and FitzGerald1 for their continued interest in our 
work. While we may not agree with their arguments or their opinions of our study2 we welcome 
debate in this extremely important area. We take this opportunity to address the points that 
they raise.  
 
First, while urine may well be a convenient compartment within which to measure markers of 
prostacyclin and thromboxane A2, numerous observations3-10, of which ours is only the latest2, 
indicate that they poorly reflect production within the circulation and the reactivities of 
endothelial cells and platelets.  
 
Second, the literature that Grosser et al. cite is somewhat selective and in places inaccurate. 
For example, reference 311, which the authors cite to substantiate the statement ‘Most insights 
into the in vivo biology and pharmacology of the prostaglandin pathway have derived from the 
measurement of metabolites, particularly in urine’ refers to a paper published in 1975 which 
makes no references to prostacyclin, PGIM, thromboxane, or TXM, being published before the 
discovery of prostacyclin12.  
 
Third, the studies selected to substantiate the point that ‘there is a striking discordance 
between the capacity of cells to make these lipids and their actual formation in vivo’ referring 
to platelet thromboxane A2 and urinary TXM, in fact, serve to corroborate the view that urinary 
prostaglandin metabolites do not necessarily reflect levels produced by vessels or platelets in 
the circulation. Indeed, Dr Fitzgerald’s own work shows that orally administered aspirin inhibits 
the formation of thromboxane by clotting blood ex vivo (which is driven by platelets) much 
more readily than it reduces the levels of urinary thromboxane metabolites 5. The simplest 
explanation for such results is that TXM does not reflect formation of thromboxane by platelets 
under physiological conditions and rather, as our study shows, can originate from the kidney2. 
 
Fourth, we were pleased to note that the authors provide no counter arguments to our 
conclusions regarding the origin of urinary PGIM in humans2. Instead the authors suggest that 
reduced PGIM in the urine of vascular COX-2 knock out mice13 supports their position. 
However, this does not prove that COX-2 drives prostacyclin in the circulation and is more 
simply explained as prostacyclin generation by vascular cells within the kidney, an organ 
where COX-2 expression is very well-characterized14, 15.  Indeed, as we4, 10 and others have 
shown repeatedly, it is COX-1, not COX-2, that is generally expressed in systemic blood 
vessels; the kidney is an exception where COX-2 is expressed.   
  
Finally, and most importantly, in direct contrast to before surgery where the patient we 
describe did have chronic renal failure which progressed to severe renal failure necessitating 
4 hours of hemodialysis 3 times per week and passing less than 500ml/day urine, after the 
kidney transplant the patient had (i) normal renal function with estimated glomerular filtration 
of greater than 70 ml/min, (ii) was not in renal failure and (iii) had no signs of inflammation 
measured as both low plasma C-reactive protein (<5) and absence of cellular infiltration in 
renal biopsies taken at 3 months post transplant.  
 
In summary, following transplantation of a healthy kidney to an individual lacking in cPLA2 
and in the complete absence of any signs of renal inflammation or dysfunction, the levels of 
urinary PGIM and TXM fall within the normal range. The simplest explanation is that the 
kidney forms PGIM and TXM.  
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